U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H21NO.ClH
Molecular Weight 291.816
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOFENACIN HYDROCHLORIDE

SMILES

Cl.CNCCOC(C1=CC=CC=C1)C2=CC=CC=C2C

InChI

InChIKey=YAXWIYFUVISXRS-UHFFFAOYSA-N
InChI=1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)17(19-13-12-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H

HIDE SMILES / InChI

Description

1-[3-(Benzyloxy)phenyl]-N,N-dimethylethanamine is an intermediate compound in the chemical synthesis of a drug Rivastigmine, which is used to treat Alzheimer's and Parkinson's disease.

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
PubMed

PubMed

TitleDatePubMed
A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy.
1976
Name Type Language
TOFENACIN HYDROCHLORIDE
MART.   MI   USAN   WHO-DD  
USAN  
Official Name English
ORPHENADRINE RELATED COMPOUND C
USP-RS  
Preferred Name English
TOFENACIN HYDROCHLORIDE [MI]
Common Name English
Tofenacin hydrochloride [WHO-DD]
Common Name English
NSC-169432
Code English
ETHANAMINE, N-METHYL-2-((2-METHYLPHENYL)PHENYLMETHOXY)-, HYDROCHLORIDE
Systematic Name English
NSC-113809
Code English
TOFENACIN HYDROCHLORIDE [USAN]
Common Name English
TOFENACIN HCL
Common Name English
ORPHENADRINE RELATED COMPOUND C [USP-RS]
Common Name English
TOFENACIN HYDROCHLORIDE [MART.]
Common Name English
N-Methyl-2-[(O-methyl-?-phenylbenzyl)oxy]ethylamine hydrochloride
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66880
Created by admin on Mon Mar 31 19:20:33 GMT 2025 , Edited by admin on Mon Mar 31 19:20:33 GMT 2025
Code System Code Type Description
NSC
113809
Created by admin on Mon Mar 31 19:20:33 GMT 2025 , Edited by admin on Mon Mar 31 19:20:33 GMT 2025
PRIMARY
FDA UNII
3A10ND4DWR
Created by admin on Mon Mar 31 19:20:33 GMT 2025 , Edited by admin on Mon Mar 31 19:20:33 GMT 2025
PRIMARY
ChEMBL
CHEMBL2110923
Created by admin on Mon Mar 31 19:20:33 GMT 2025 , Edited by admin on Mon Mar 31 19:20:33 GMT 2025
PRIMARY
RS_ITEM_NUM
1479031
Created by admin on Mon Mar 31 19:20:33 GMT 2025 , Edited by admin on Mon Mar 31 19:20:33 GMT 2025
PRIMARY
CAS
10488-36-5
Created by admin on Mon Mar 31 19:20:33 GMT 2025 , Edited by admin on Mon Mar 31 19:20:33 GMT 2025
PRIMARY
MERCK INDEX
m970
Created by admin on Mon Mar 31 19:20:33 GMT 2025 , Edited by admin on Mon Mar 31 19:20:33 GMT 2025
PRIMARY Merck Index
PUBCHEM
25314
Created by admin on Mon Mar 31 19:20:33 GMT 2025 , Edited by admin on Mon Mar 31 19:20:33 GMT 2025
PRIMARY
EVMPD
SUB04904MIG
Created by admin on Mon Mar 31 19:20:33 GMT 2025 , Edited by admin on Mon Mar 31 19:20:33 GMT 2025
PRIMARY
NSC
169432
Created by admin on Mon Mar 31 19:20:33 GMT 2025 , Edited by admin on Mon Mar 31 19:20:33 GMT 2025
PRIMARY
ECHA (EC/EINECS)
234-011-9
Created by admin on Mon Mar 31 19:20:33 GMT 2025 , Edited by admin on Mon Mar 31 19:20:33 GMT 2025
PRIMARY
NCI_THESAURUS
C81452
Created by admin on Mon Mar 31 19:20:33 GMT 2025 , Edited by admin on Mon Mar 31 19:20:33 GMT 2025
PRIMARY
SMS_ID
100000084633
Created by admin on Mon Mar 31 19:20:33 GMT 2025 , Edited by admin on Mon Mar 31 19:20:33 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of TOFENACIN
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966